Thor Medical

TRMED

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Mindre end 1K følgere

Thor Medical is a pharmaceutical company. The company specializes in the development of antibody drugs for the treatment of hematological cancer. The greatest specialization is found in precision therapy used in the clinical phase. Other diseases that are treated are non-Hodgkin's lymphoma (NHL). The company was founded in 2009 and is headquartered in Oslo, Norway.

Markedsværdi

-

Aktieomsætning

-

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Finanskalender

26.2

2025

Årsrapport '24

24.4

2025

Generalforsamling '25

29.8

2025

Delårsrapport Q2'25

ViserAlle indholdstyper

Selskabsmeddelelsefor 5 timer siden

Thor Medical ASA: Notification of trade for close associate of primary insider

Selskabsmeddelelsefor 5 timer siden

Thor Medical ASA: Final results of the Subsequent Offering

Selskabsmeddelelsefor 18 timer siden

Thor Medical ASA: The Subscription Period in the Subsequent Offering ends today at 12:30 CET

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Selskabsmeddelelse16.1.2025, 15.27

TRMED: Financial calendar

Selskabsmeddelelse15.1.2025, 09.31

Thor Medical ASA: Share capital increase in relation to Tranche 2 of the Private Placement is registered

Selskabsmeddelelse13.1.2025, 06.00

Thor Medical ASA: Commencement of the subscription period for the subsequent offering

Selskabsmeddelelse10.1.2025, 12.30

Thor Medical ASA: Approval of prospectus and launch of subsequent offering

Selskabsmeddelelse7.1.2025, 06.45

TRMED: Thor Medical secures NOK 90 million loan from Innovation Norway, ensuring full financing of AlphaOne

Selskabsmeddelelse20.12.2024, 14.06

Thor Medical ASA: Notification of trade for close associate of primary insider

Selskabsmeddelelse20.12.2024, 13.26

Thor Medical ASA: Disclosure of large shareholding

Selskabsmeddelelse20.12.2024, 13.23

Thor Medical ASA: Disclosure of large shareholdings and notification of transaction by close associates of primary insiders

Selskabsmeddelelse20.12.2024, 13.17

Thor Medical ASA - Share capital increase in relation to Tranche 1 of the Private Placement and the PrimaryBid Offering is registered

Selskabsmeddelelse19.12.2024, 06.45

TRMED: Thor Medical and AdvanCell sign strategic supply agreement for Thorium-228

Selskabsmeddelelse16.12.2024, 19.34

Thor Medical ASA - Notice of Extraordinary General Meeting on 6 January 2025

Selskabsmeddelelse12.12.2024, 06.00

Thor Medical ASA: Ex. right to participate in subsequent offering today

Selskabsmeddelelse11.12.2024, 23.59

Thor Medical ASA: Disclosure of large shareholding - share lending

Selskabsmeddelelse11.12.2024, 23.55

Thor Medical ASA: Allocation of shares to primary insiders and their close associates in the Private Placement

Selskabsmeddelelse11.12.2024, 23.43

Thor Medical ASA: Key information relating to potential subsequent offering

Selskabsmeddelelse11.12.2024, 23.31

Thor Medical ASA: Private placement successfully completed

Selskabsmeddelelse11.12.2024, 15.30

Thor Medical ASA: Contemplated private placement and retail offer via PrimaryBid

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.